Xu Cai1, Ming Yang. 1. Department of Orthopedics, Division of Surgery, Chinese PLA General Hospital, Beijing, China.
Abstract
PURPOSE: The P53-MDM2 pathway plays a central role in sarcoma pathogenesis. Functional P53 Arg72Pro and MDM2 T309G single-nucleotide polymorphisms (SNP) are considered to have significant effects on risk of sarcomas. METHODS: Several molecular epidemiology studies have evaluated how these genetic variants are involved in sarcoma development, but the conclusions are inconsistent. Therefore, we conducted this meta-analysis to systematically examine the association between these functional SNPs and sarcoma risk. RESULTS: There are four studies eligible for P53 Arg72Pro SNP (466 sarcoma patients and 552 controls), and three studies for MDM2 T309G SNP (355 sarcoma patients and 645 controls). Pooled odds ratios were appropriately calculated using either fixed-effect model or random-effect model. We did not find a significant association between P53 Arg72Pro polymorphism and sarcoma risk. However, in a stratified analysis, a statistically significant correlation between this SNP and osteosarcoma risk was observed. For MDM2 T309G variant, pooled results from the meta-analysis indicate that carriers of TG and GG genotypes showed a 34% increased risk to develop sarcomas compared to TT carriers. CONCLUSION: These results suggest that the functional MDM2 T309G genetic variant may play a more important role in carcinogenesis of sarcoma.
PURPOSE: The P53-MDM2 pathway plays a central role in sarcoma pathogenesis. Functional P53 Arg72Pro and MDM2T309G single-nucleotide polymorphisms (SNP) are considered to have significant effects on risk of sarcomas. METHODS: Several molecular epidemiology studies have evaluated how these genetic variants are involved in sarcoma development, but the conclusions are inconsistent. Therefore, we conducted this meta-analysis to systematically examine the association between these functional SNPs and sarcoma risk. RESULTS: There are four studies eligible for P53 Arg72Pro SNP (466 sarcomapatients and 552 controls), and three studies for MDM2T309G SNP (355 sarcomapatients and 645 controls). Pooled odds ratios were appropriately calculated using either fixed-effect model or random-effect model. We did not find a significant association between P53 Arg72Pro polymorphism and sarcoma risk. However, in a stratified analysis, a statistically significant correlation between this SNP and osteosarcoma risk was observed. For MDM2T309G variant, pooled results from the meta-analysis indicate that carriers of TG and GG genotypes showed a 34% increased risk to develop sarcomas compared to TT carriers. CONCLUSION: These results suggest that the functional MDM2T309G genetic variant may play a more important role in carcinogenesis of sarcoma.
Authors: Moriko Ito; Louise Barys; Terence O'Reilly; Sophie Young; Bella Gorbatcheva; John Monahan; Sabine Zumstein-Mecker; Peter F Choong; Ian Dickinson; Philip Crowe; Christine Hemmings; Jayesh Desai; David M Thomas; Joanna Lisztwan Journal: Clin Cancer Res Date: 2010-12-15 Impact factor: 12.531
Authors: D Polsky; B C Bastian; C Hazan; K Melzer; J Pack; A Houghton; K Busam; C Cordon-Cardo; I Osman Journal: Cancer Res Date: 2001-10-15 Impact factor: 12.701
Authors: F M Buonaguro; M L Tornesello; E Beth-Giraldo; A Hatzakis; N Mueller; R Downing; B Biryamwaho; S D Sempala; G Giraldo Journal: Int J Cancer Date: 1996-01-03 Impact factor: 7.396
Authors: Helena S Thurow; Fernando P Hartwig; Clarice S Alho; Deborah S B S Silva; Rafael Roesler; Ana Lucia Abujamra; Caroline Brunetto de Farias; Algemir Lunardi Brunetto; Bernardo L Horta; Odir A Dellagostin; Tiago Collares; Fabiana K Seixas Journal: Mol Biol Rep Date: 2013-05-10 Impact factor: 2.316